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Introduction
Due in part to disproportionate prescription of antibiotics during the latter half of the 20 th century, the past 2 decades have seen the inevitable emergence of bacterial resistance to all currently available therapeutic agents. [1] Of particular concern are the so-called 'ESKAPE' pathogens (multi-drug resistant Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), which cause infections associated with elevated rates of morbidity and mortality. [2, 3] The need for antibiotics based upon novel chemotypes which act upon novel molecular targets has long been recognised as critical to the future management of the problem. A recent manifestation of this concept is the 'ten-by-twenty' initiative, a gauntlet thrown down by the Infectious Diseases Society of America (IDSA) to those involved in antimicrobial drug discovery, urging a more concerted effort with the goal of delivering 10 new antibacterial drugs by 2020. [4] DNA gyrase and the structurally homologous enzyme topoisomerase IV (topo IV) are highly conserved ATP dependant bacterial type IIa topoisomerase enzymes which play an essential role within bacteria linked to the conservation of chromosomal integrity during DNA replication and transcription. [5] These enzymes have long been validated as therapeutic drug targets owing to the commercial and clinical success of members of the fluoroquinolone antibiotic class (e.g. ciprofloxacin, gemifloxacin) which target the catalytic (GyrA / ParC) sub-units in a dual-inhibitory fashion. [6] More recently, the development of small molecule ATPase inhibitors of gyrase (GyrB) and topo IV (ParE), aided by the elucidation of proteinligand structures of GyrB, has gained attention as a means to inhibit these classical enzyme targets in the pursuit of novel antibacterial compounds. [7] [8] [9] [10] Encouraged by these reports, our interest in the discovery of novel ATPase inhibitors of GyrB / ParE began with the observation that a number of reports in the literature demonstrated that heterocyclic N-ethylurea derivatives to be conducive with potent dualinhibitory ATPase activity coupled to antimicrobial activity. [7, 8, 10, 11] . Notably, benzimidazol-2-yl-ureas (1), benzathiazol-2-yl-ureas (2), imidazopyridin-2-yl-ureas (3), triazolopyridine-5-carboxamides (4), isoquinolin-3-yl-ureas (5) and pyridin-3-yl-ureas (6) reported by groups at Vertex [7] , Prolysis 11 , Pfizer [10] , Evotec [8] , Actelion [12] and AstraZeneca [13] respectively, exemplify the prevalence of this moiety amongst antibacterial GyrB / ParE inhibitors ( Fig. 1) . 
Molecular design of inhibitors
Employing an in house crystal structure depicting the ATP binding domain of GyrB, we explored and modeled a number of alternative heterocyclic core scaffolds which, when coupled to the N-ethylurea side-chain, were predicted to have the potential for potent GyrB inhibitory activity whilst offering distinct advantages in terms of optimisation opportunities to compounds 1 -6. Specifically, the de novo design software SPROUT [14] From a synthetic viewpoint, the most attractive structure to emerge from this process was based on a pyridine-3-carboxamide (7) core ( Figure 3 ). Docking of this structure into the ATP binding site within the protein using AutoDock [15] acted as an independent check and confirmed that key binding interactions of known importance to GyrB / ParE inhibition would be maintained. These include hydrogen bonds to Asn-55 / Asp-82 and an arylstack interaction with Arg-85 (Enterococcus faecalis GyrB numbering, Figure 4 ) [16] .
Although treated as neutral by AutoDock during the docking process, Arg-85 is likely to be positively charged under physiological conditions, and therefore interaction of this residue with the pyridine ring may be expected to have both -and -cation character. 
Synthesis of putative inhibitors
To test the modelling hypothesis, compound 7 was prepared according to the procedure described in Scheme 1 from commercially available 6-aminonicotinate 8. c data from Starr et al. [10] ; d data from East et al. [8] As indicated from inspection of the data in Table 1 , although compound 7 synthesised as part of the present work was 1 -2 orders of magnitude less potent against GyrB than those previously reported, this was encouraging given the lower molecular weight / complexity of this inhibitor. Furthermore, the antimicrobial activity found for this compound, albeit weak, indicated the potential for optimisation. We therefore elected that our continuing investigation would focus on further developing these pyridine-3-carboxamides.
C3 position SAR
Our initial SAR investigation concerned variation of the aryl moiety at the pyridyl C3 position of structure 7 and the target molecules were accessed conveniently through coupling of nicotinic acid 10 with commercially available aromatic amines (Scheme 1, Table 2 ). We reasoned that variation here could increase the importance of the -stacking with Arg-85.
Biological data is given in Table 2 . In general, substituted phenyl derivatives (entries 11 -21) led to improvements in enzyme potency and some MICs were also improved relative to compound 7. In particular the ortho-chloro compound 12 (GyrB IC 50 1.6 µM, MIC 16 µg / mL SA, EF, SP) demonstrated a good balance between enzyme and cellular potency. Potent GyrB inhibitors were also identified when the C3 substituent was a 5-membered heterocycle.
Thiazole compounds 25 and 26 have IC 50 s of 420 nM and 960 nM respectively, though these compounds did not demonstrate measurable antibacterial activity in the strains tested ( 
Variation of the C4 position: Synthesis and SAR
According to our earlier modelling (Fig. 3) , a sizeable sub-pocket was predicted such that substitution at the pyridyl C4 position in structure 7 was highlighted as an option for structural optimisation. Synthetic routes to these compounds are summarised in Schemes 2 - Biological data for the C4 substituted pyridine-3-carboxamides is given in Tables 3 and 4 .
Additionally, in order to probe the suitability of these compounds for broad spectrum These additional data are presented in Table 5 . As indicated from inspection of the data in Table 3 was modelled within the E. faecalis ATP binding domain (Fig. 5) . Again, important polar contacts were predicted to be maintained and it appeared plausible that ligand 'preorganisation' through an internal hydrogen bond involving the carbonyl at C3 and the NH at C4 may explain the improvement in potency. A number of compounds were synthesised to further explore this phenomenon through preservation of the C4 amino-aryl motif (Table 4) . In this instance, simple, unsubstituted phenyl / pyridine-3-yl moieties were chosen and found to be adequate replacements for the m-toluidyl group present in compound 33. Compounds featuring the amino-aryl appendage were predominantly found to have potent GyrB inhibitory activity (IC 50 s < 500 nM) and
Gram positive antibacterial activity (MICs 0.125 -2 µg / mL). Tellingly, C4 O-aryl compound 85, which lacks the ability to form an internal hydrogen bond, is comparatively inactive and had no antibacterial activity (GyrB IC 50 4.9 µM). Para substitution at the C3 aromatic group was found to be well tolerated, with compounds 81 -83 designed to probe the solvent exposed area of the binding pocket using morpholine, acetamide and triazole side- (Table 4) . Table 4 GyrB inhibitory activity and MICs for C4 amino-aryl pyridine-3-carboxamides. Table 5 were active against the efflux knock-out mutant indicating that active efflux plays a role in the lack of Gram negative activity of this compound class. The MICs for these three compounds were higher against the efflux-knock out E. coli than against wild type S. aureus suggesting that they are not able to permeate Gram negative cells as effectively as Gram positive cells. Subsequently a small library of compounds was synthesised with the goal of investigating alternative substitution at the C4 position (Schemes 4 and 5). Hydroxy-and methoxy-phenyl derivatives were chosen, as docking indicated that the C4 group would be oriented in a solvent exposed area, and more polar substituents would be predicted to experience stabilisation in the water-exposed region. Enzyme inhibition was measured against both GyrB and ParE enzymes from E. coli and S. aureus and MICs were measured against both S.
aureus and E. coli (Table 6 ). In keeping with our previous observations, none of the compounds synthesised showed meaningful activity against the Gram negative species suggesting that simple variation at the C4 position is insufficient to provide compounds with
Gram negative activity. All compounds showed good inhibitory activity against GyrB and reasonable activity against ParE, although they were less active against ParE from E. coli which may offer an additional barrier to activity of these compounds in Gram negative bacteria. 
Conclusion
In summary we have reported the discovery, synthesis and an initial SAR study of a novel series of antibacterial GyrB inhibitors. Through structural optimisation we have developed the pyridine-3-carboxamide-6-yl-urea core to offer derivatives with excellent GyrB inhibitory activity and Gram positive antibacterial efficacy. A key activity breakthrough via the introduction of amino-aryl i.e. NH-aryl functionality at the pyridyl C4 position is reported. Encouragingly, inhibitors were identified (e.g. compound 80) which demonstrate broad spectrum Gram positive antibacterial activity, activity against a Gram negative efflux pump mutant, and activity versus single-step GyrB / ParE mutants. These observations may prove important in the future therapeutic utility of this compound class. Compounds reported in this paper have been patented [20] . Further optimisation of compounds in this series is ongoing, with a focus on modification of physicochemical properties with the hopes of broadening their spectrum of activity to include Gram negative organisms.
